Cover Image
市場調查報告書

先天性遺傳基因·染色體異常遺傳基因檢驗:開發平台分析

Inborn Gene or Chromosome Alterations Diagnostic Tests - Medical Devices Pipeline Assessment, 2017

出版商 GlobalData 商品編碼 342293
出版日期 內容資訊 英文 429 Pages
訂單完成後即時交付
價格
Back to Top
先天性遺傳基因·染色體異常遺傳基因檢驗:開發平台分析 Inborn Gene or Chromosome Alterations Diagnostic Tests - Medical Devices Pipeline Assessment, 2017
出版日期: 2017年10月01日 內容資訊: 英文 429 Pages
簡介

本報告提供全球各國的企業·醫療機關等正在開發的先天性遺傳基因·染色體異常遺傳基因檢驗的相關產品 (檢查裝置·試劑等) 之開發中產品資訊相關分析,提供您臨床實驗/產品開發的整體進展,及各階段·各領域·各地區的詳細趨勢,各企業·各產品的詳細資訊 (臨床實驗的進展階段,開始/結束時期,認證預測等),近來的產品開發的動向·產業趨勢等資料,為您概述為以下內容。

第1章 目錄

第2章 簡介

  • 先天性遺傳基因·染色體異常 (變性) 轉動遺傳基因檢驗概要

第3章 開發中的產品

  • 開發中產品:各開發階段
  • 開發中產品:各地區
  • 開發中產品:各法規途徑
  • 開發中產品:各核審時期 (估計)
  • 現在進行中的臨床實驗

第4章 先天性遺傳基因·染色體異常遺傳基因檢驗:正在開發的開發中產品 (各企業)

  • 先天性遺傳基因·染色體異常遺傳基因檢驗的開發企業:開發中產品 (各開發階段)
  • 先天性遺傳基因·染色體異常遺傳基因檢驗:各開發階段的開發中產品一覽

第5章 先天性遺傳基因·染色體異常遺傳基因檢驗的開發企業·產品概要

  • AC-Gen Reading Life S.L.
    • 開發中產品及現在進行中的臨床實驗概要
  • Admera Health, LLC
  • Agena Bioscience, Inc
  • Ariosa Diagnostics, Inc.
  • Atomic International
  • Baylor College of Medicine
  • BCML GmbH
  • BioCeps (Inactive)
  • CardioDx, Inc.
  • Celera Corporation
  • Celula, Inc.
  • Children's Hospital Boston
  • China Medical Technologies, Inc.
  • Da An Gene Co., Ltd.
  • Dana-Farber Cancer Institute, Inc.
  • Epinex Diagnostics Incorporated
  • Genentech, Inc.
  • German Cancer Research Center
  • GILUPI Nanomedizin
  • Hadassah Medical Center
  • Helicos BioSciences Corporation
  • Illumina, Inc.
  • IntegraGen SA
  • Interleukin Genetics, Inc.
  • JS Genetics Inc.
  • Laboratory Corporation of America Holdings
  • Laval University
  • LifeCodexx AG
  • Maastricht University Medical Center
  • Massachusetts Eye and Ear Infirmary
  • Medical Research Council
  • Micromedic Technologies Ltd
  • Multiplicom N.V.
  • Myriad Genetics, Inc.
  • Natera, Inc.
  • National University of Singapore
  • NewGene Ltd
  • NX PharmaGen Inc.
  • Paragon Medical, Inc.
  • Population Diagnostics Inc.
  • Qiagen N.V.
  • Quantamerix
  • Sapien Biosciences
  • Seegene, Inc.
  • Sequenom, Inc.
  • Stanford University
  • The Johns Hopkins University
  • The Sheba Medical Center
  • The University of Utah
  • TrovaGene, Inc.
  • University of Colorado
  • University of Washington
  • VitaPath Genetics, Inc.
  • Xiamen Zeesan Biotech Co.,Ltd
  • Yale University

第6章 先天性遺傳基因·染色體異常遺傳基因檢驗:近來的市場趨勢

第7章 附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDME0452EPD

GlobalData's Medical Devices sector report, "Inborn Gene or Chromosome Alterations Diagnostic Tests - Medical Devices Pipeline Assessment, 2017" provides an overview of Inborn Gene or Chromosome Alterations Diagnostic Tests currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Inborn Gene or Chromosome Alterations Diagnostic Tests pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

  • Extensive coverage of the Inborn Gene or Chromosome Alterations Diagnostic Tests under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Inborn Gene or Chromosome Alterations Diagnostic Tests and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry

Reasons to buy

The report enables you to -

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Inborn Gene or Chromosome Alterations Diagnostic Tests under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product's current stage of development, territory and estimated launch date

Table of Contents

1 Table of Contents

1 Table of Contents 2

  • 1.1 List of Tables 9
  • 1.2 List of Figures 20

2 Introduction 21

  • 2.1 Inborn Gene or Chromosome Alterations Diagnostic Tests Overview 21

3 Products under Development 22

  • 3.1 Inborn Gene or Chromosome Alterations Diagnostic Tests - Pipeline Products by Stage of Development 22
  • 3.2 Inborn Gene or Chromosome Alterations Diagnostic Tests - Pipeline Products by Territory 23
  • 3.3 Inborn Gene or Chromosome Alterations Diagnostic Tests - Pipeline Products by Regulatory Path 24
  • 3.4 Inborn Gene or Chromosome Alterations Diagnostic Tests - Pipeline Products by Estimated Approval Date 25
  • 3.5 Inborn Gene or Chromosome Alterations Diagnostic Tests - Ongoing Clinical Trials 26

4 Inborn Gene or Chromosome Alterations Diagnostic Tests - Pipeline Products under Development by Companies 27

  • 4.1 Inborn Gene or Chromosome Alterations Diagnostic Tests Companies - Pipeline Products by Stage of Development 27
  • 4.2 Inborn Gene or Chromosome Alterations Diagnostic Tests - Pipeline Products by Stage of Development 32

5 Inborn Gene or Chromosome Alterations Diagnostic Tests Companies and Product Overview 39

  • 5.1 3D Signatures Inc Company Overview 39
  • 5.2 AbaStar MDx Inc Company Overview 40
  • 5.3 Abital Pharma Pipelines Ltd Company Overview 43
  • 5.4 Agena Bioscience, Inc Company Overview 44
  • 5.5 AIT Austrian Institute of Technology GmbH Company Overview 45
  • 5.6 Alexion Pharmaceuticals Inc Company Overview 46
  • 5.7 Amarantus Bioscience Holdings Inc Company Overview 47
  • 5.8 Amity University Company Overview 48
  • 5.9 Ariosa Diagnostics Inc Company Overview 49
  • 5.10 Arrayit Diagnostics, Inc. Company Overview 50
  • 5.11 Asuragen Inc Company Overview 51
  • 5.12 Augusta University Company Overview 52
  • 5.13 AutoGenomics Inc Company Overview 53
  • 5.14 Avellino Lab USA Inc Company Overview 63
  • 5.15 Baylor College of Medicine Company Overview 64
  • 5.16 BCML GmbH Company Overview 65
  • 5.17 BioCeps (Inactive) Company Overview 66
  • 5.18 Biocept Inc Company Overview 67
  • 5.19 Celula Inc Company Overview 68
  • 5.20 Center for Biomedical Research in Network of Rare Diseases Company Overview 69
  • 5.21 Children's Hospital Boston Company Overview 70
  • 5.22 China Medical Technologies Inc (Inactive) Company Overview 72
  • 5.23 ChipCare Corp Company Overview 73
  • 5.24 Chronix Biomedical Inc Company Overview 74
  • 5.25 Cincinnati Children's Hospital Medical Center Company Overview 75
  • 5.26 Columbia University Company Overview 80
  • 5.27 Da An Gene Co Ltd Company Overview 82
  • 5.28 Decipher GenX, Inc. Company Overview 84
  • 5.29 D-Kimia, LLC. Company Overview 87
  • 5.30 Duke University Company Overview 89
  • 5.31 DxTerity Diagnostics Inc Company Overview 90
  • 5.32 ELITechGroup Inc Company Overview 91
  • 5.33 Epinex Diagnostics Inc Company Overview 92
  • 5.34 Eppendorf AG Company Overview 93
  • 5.35 Fina Biotech SL Company Overview 94
  • 5.36 Firalis SAS Company Overview 95
  • 5.37 Fluidigm Corp Company Overview 96
  • 5.38 Fraunhofer-Gesellschaft zur Forderung der Angewandten Forschung eV Company Overview 97
  • 5.39 French National Institute of Health and Medical Research Company Overview 98
  • 5.40 Genekam Biotechnology AG Company Overview 101
  • 5.41 Genentech Inc Company Overview 102
  • 5.42 Genetic Analysis AS Company Overview 103
  • 5.43 GENEWIZ Inc Company Overview 105
  • 5.44 German Cancer Research Center Company Overview 106
  • 5.45 German Institute of Human Nutrition Company Overview 109
  • 5.46 GILUPI Nanomedizin Company Overview 110
  • 5.47 Good Start Genetics Inc Company Overview 111
  • 5.48 Goodgene Inc Company Overview 113
  • 5.49 Hadassah Medical Center Company Overview 114
  • 5.50 Helicos BioSciences Corporation Company Overview 115
  • 5.51 Helmholtz Center for Health and the Environment Munich Company Overview 116
  • 5.52 Illumina, Inc. Company Overview 118
  • 5.53 Immunexpress Pty Ltd Company Overview 121
  • 5.54 Inform Genomics Inc Company Overview 124
  • 5.55 Interleukin Genetics Inc Company Overview 126
  • 5.56 International Biomedical Company Overview 127
  • 5.57 Interpace Diagnostics, LLC Company Overview 128
  • 5.58 John Hopkins University Company Overview 130
  • 5.59 JS Genetics Inc Company Overview 133
  • 5.60 Juneau Biosciences LLC Company Overview 134
  • 5.61 KellBenx Inc Company Overview 136
  • 5.62 Laboratory Corp of America Holdings Company Overview 138
  • 5.63 Laval University Company Overview 139
  • 5.64 LifeCodexx AG Company Overview 140
  • 5.65 LineaGen Inc Company Overview 141
  • 5.66 Maastricht University Medical Center Company Overview 142
  • 5.67 Massachusetts Eye and Ear Infirmary Company Overview 143
  • 5.68 Max-Delbruck-Centrum fur Molekulare Medizin (MDC) Company Overview 145
  • 5.69 Medical Research Council Company Overview 146
  • 5.70 Multiplicom NV Company Overview 147
  • 5.71 Nanosphere Inc Company Overview 148
  • 5.72 National Institute of Immunohaematology Company Overview 150
  • 5.73 National University of Singapore Company Overview 151
  • 5.74 NewGene Ltd Company Overview 153
  • 5.75 Northwestern University Company Overview 156
  • 5.76 NX PharmaGen Inc Company Overview 157
  • 5.77 OncoGenesis Company Overview 158
  • 5.78 Oxford Biodynamics Plc Company Overview 159
  • 5.79 Oxford Gene Technology Ltd Company Overview 175
  • 5.80 Paragon Medical Inc Company Overview 176
  • 5.81 Population Bio Inc Company Overview 177
  • 5.82 PreCyte, Inc. Company Overview 188
  • 5.83 Predictive Therapeutics LLC Company Overview 189
  • 5.84 Premaitha Health Plc Company Overview 192
  • 5.85 Prenetics Inc Company Overview 194
  • 5.86 Prognomix Inc Company Overview 195
  • 5.87 Proove BioScience Inc Company Overview 197
  • 5.88 Quest Diagnostics Inc Company Overview 200
  • 5.89 R-Biopharm AG Company Overview 205
  • 5.90 Sansure Biotech Inc Company Overview 206
  • 5.91 Sapien Biosciences Company Overview 207
  • 5.92 Seattle Children's Hospital Company Overview 209
  • 5.93 Sequenom Inc Company Overview 210
  • 5.94 Sequoia Genetics Company Overview 212
  • 5.95 Sheba Medical Center Company Overview 213
  • 5.96 SkylineDx BV Company Overview 214
  • 5.97 Spartan Bioscience Inc Company Overview 215
  • 5.98 Strand Life Sciences Pvt Ltd Company Overview 216
  • 5.99 SUNY Upstate Medical University Company Overview 218
  • 5.100 TAmiRNA GmbH Company Overview 219
  • 5.101 TBG Diagnostics Ltd Company Overview 220
  • 5.102 Tel Aviv University Company Overview 221
  • 5.103 Transgenomic Inc Company Overview 222
  • 5.104 Transplant Genomics Inc. Company Overview 223
  • 5.105 TrovaGene Inc Company Overview 226
  • 5.106 Tufts Medical Center Company Overview 228
  • 5.107 University Hospital of Cologne Company Overview 229
  • 5.108 University of Arizona Company Overview 232
  • 5.109 University of California San Francisco Company Overview 233
  • 5.110 University of Cape Town Company Overview 234
  • 5.111 University of Central Florida Company Overview 235
  • 5.112 University of Colorado Company Overview 237
  • 5.113 University of Illinois at Chicago Company Overview 238
  • 5.114 University of Maryland Company Overview 239
  • 5.115 University of Michigan Company Overview 240
  • 5.116 University of Utah Company Overview 242
  • 5.117 Vaiomer SAS Company Overview 243
  • 5.118 Vanadis Diagnostics AB Company Overview 245
  • 5.119 Veritas Genetics Company Overview 246
  • 5.120 VitaPath Genetics, Inc. Company Overview 248
  • 5.121 Weizmann Institute of Science Company Overview 249
  • 5.122 Xiamen Zeesan Biotech Co.,Ltd Company Overview 250
  • 5.123 XRGenomics LTD Company Overview 251
  • 5.124 Yale University Company Overview 253
  • 5.125 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd Company Overview 255

6 Inborn Gene or Chromosome Alterations Diagnostic Tests- Recent Developments 257

  • 6.1 Sep 07, 2017: Further patent infringement claims received from Illumina & Sequenom 257
  • 6.2 Sep 07, 2017: Eurofins Genoma Introduces GeneSafe - The First Non-Invasive Prenatal Test That Screens for Single-Gene Disorders 257
  • 6.3 Aug 29, 2017: Premaitha approved for Good Manufacturing Practice by ANVISA Brazil 258
  • 6.4 Aug 24, 2017: LabCorp Names Nationally Recognized Health-Policy Expert Dr. Brian Caveney As Enterprise-Wide Chief Medical Officer 258
  • 6.5 Aug 15, 2017: GeneNews Announces Q2-2017 Financial Results & Provides Progress Update 259
  • 6.6 Aug 09, 2017: Trovagene Announces Second Quarter 2017 Company Highlights and Financial Results 260
  • 6.7 Aug 08, 2017: Natera Reports Second Quarter 2017 Financial Results 262
  • 6.8 Aug 07, 2017: Luminex Reports Second Quarter 2017 Financial Results 263
  • 6.9 Aug 03, 2017: Fluidigm Announces Second Quarter Financial Results and Operational Progress 264
  • 6.10 Aug 03, 2017: CombiMatrix Reports Second Quarter 2017 Financial and Operating Results 265
  • 6.11 Aug 02, 2017: Hologic Announces Financial Results for Third Quarter of Fiscal 2017 266
  • 6.12 Aug 01, 2017: GenMark Reports Second Quarter 2017 Results 268
  • 6.13 Aug 01, 2017: llumina Reports Strong Financial Results for Second Quarter of Fiscal Year 2017 269
  • 6.14 Aug 01, 2017: Novel Genetic Test Could Help Combat the Opioid Epidemic by Identifying Patients at Risk of Addiction 270
  • 6.15 Aug 01, 2017: Illumina Reports Strong Financial Results for Second Quarter of Fiscal Year 2017 270
  • 6.16 Jul 28, 2017: ORYZON Reports Financial Results and Corporate Update for the 1st Half Ended June 30, 2017 271
  • 6.17 Jul 27, 2017: QIAGEN Reports Results for Second Quarter and First Half of 2017 273
  • 6.18 Jul 26, 2017: LabCorp Announces Record Results in the Second Quarter of 2017 and Increases 2017 Guidance 276
  • 6.19 Jul 26, 2017: Thermo Fisher Scientific Reports Second Quarter 2017 Results 279
  • 6.20 Jul 25, 2017: Quest Diagnostics Reports Second Quarter 2017 Financial Results, Raises 2017 Financial Outlook 281
  • 6.21 Jul 18, 2017: LabCorp's William Hanlon Appointed to Governing Committee of the National Evaluation System for health Technology Coordinating Center 281
  • 6.22 Jul 11, 2017: Integragen Reports Continued Growth During 1st Half Of 2017 282
  • 6.23 Jul 10, 2017: Premaitha announces two laboratory hub contracts in South East Asia 282
  • 6.24 Jul 10, 2017: Trovagene Regains Compliance with NASDAQ Listing Requirements 283
  • 6.25 Jul 03, 2017: Premaitha Health Litigation Update 283
  • 6.26 Jul 03, 2017: Interleukin Genetics To Explore Strategic Alternatives, Reduce Workforce 283

7 Appendix 423

  • 7.1 Methodology 423
  • 7.2 About GlobalData 426
  • 7.3 Contact Us 426
  • 7.4 Disclaimer 426

List of Tables

1.1 List of Tables

  • Table 1: Inborn Gene or Chromosome Alterations Diagnostic Tests - Pipeline Products by Stage of Development 25
  • Table 2: Inborn Gene or Chromosome Alterations Diagnostic Tests - Pipeline Products by Territory 26
  • Table 3: Inborn Gene or Chromosome Alterations Diagnostic Tests - Pipeline Products by Regulatory Path 27
  • Table 4: Inborn Gene or Chromosome Alterations Diagnostic Tests - Pipeline Products by Estimated Approval Date 28
  • Table 5: Inborn Gene or Chromosome Alterations Diagnostic Tests - Ongoing Clinical Trials 29
  • Table 6: Inborn Gene or Chromosome Alterations Diagnostic Tests Companies - Pipeline Products by Stage of Development 30
  • Table 7: Inborn Gene or Chromosome Alterations Diagnostic Tests - Pipeline Products by Stage of Development 35
  • Table 8: 3D Signatures Inc Pipeline Products & Ongoing Clinical Trials Overview 42
  • Table 9: 3D Telo-AD Test - Product Status 42
  • Table 10: 3D Telo-AD Test - Product Description 42
  • Table 11: AbaStar MDx Inc Pipeline Products & Ongoing Clinical Trials Overview 43
  • Table 12: Molecular Diagnostic Test - Bipolar Disorder - Product Status 43
  • Table 13: Molecular Diagnostic Test - Bipolar Disorder - Product Description 43
  • Table 14: Molecular Diagnostic Test - Depression - Product Status 44
  • Table 15: Molecular Diagnostic Test - Depression - Product Description 44
  • Table 16: Molecular Diagnostic Test - Parkinson's Disease - Product Status 44
  • Table 17: Molecular Diagnostic Test - Parkinson's Disease - Product Description 45
  • Table 18: Molecular Diagnostic Test - Schizophrenia - Product Status 45
  • Table 19: Molecular Diagnostic Test - Schizophrenia - Product Description 45
  • Table 20: Abital Pharma Pipelines Ltd Pipeline Products & Ongoing Clinical Trials Overview 46
  • Table 21: Diagnostic Assay - Parkinson's Disease - Product Status 46
  • Table 22: Diagnostic Assay - Parkinson's Disease - Product Description 46
  • Table 23: Agena Bioscience, Inc Pipeline Products & Ongoing Clinical Trials Overview 47
  • Table 24: Sensigene Trisomy 21 Laboratory Developed Test - Product Status 47
  • Table 25: Sensigene Trisomy 21 Laboratory Developed Test - Product Description 47
  • Table 26: AIT Austrian Institute of Technology GmbH Pipeline Products & Ongoing Clinical Trials Overview 48
  • Table 27: Diagnostic Tool - Fibroproliferative Wound Healing - Product Status 48
  • Table 28: Diagnostic Tool - Fibroproliferative Wound Healing - Product Description 48
  • Table 29: Alexion Pharmaceuticals Inc Pipeline Products & Ongoing Clinical Trials Overview 49
  • Table 30: SmartPanel - Product Status 49
  • Table 31: SmartPanel - Product Description 49
  • Table 32: Amarantus Bioscience Holdings Inc Pipeline Products & Ongoing Clinical Trials Overview 50
  • Table 33: Diagnostic Test - IFN-Beta Resistance - Product Status 50
  • Table 34: Diagnostic Test - IFN-Beta Resistance - Product Description 50
  • Table 35: Amity University Pipeline Products & Ongoing Clinical Trials Overview 51
  • Table 36: Prenatal Screening Kit - Product Status 51
  • Table 37: Prenatal Screening Kit - Product Description 51
  • Table 38: Ariosa Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 52
  • Table 39: Harmony Prenatal Test - Product Status 52
  • Table 40: Harmony Prenatal Test - Product Description 52
  • Table 41: Arrayit Diagnostics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 53
  • Table 42: PDx Pre-Symptomatic Test - Product Status 53
  • Table 43: PDx Pre-Symptomatic Test - Product Description 53
  • Table 44: Asuragen Inc Pipeline Products & Ongoing Clinical Trials Overview 54
  • Table 45: Signature CF Expand - Product Status 54
  • Table 46: Signature CF Expand - Product Description 54
  • Table 47: Augusta University Pipeline Products & Ongoing Clinical Trials Overview 55
  • Table 48: SUMO Gene Test - Type 1 Diabetes - Product Status 55
  • Table 49: SUMO Gene Test - Type 1 Diabetes - Product Description 55
  • Table 50: AutoGenomics Inc Pipeline Products & Ongoing Clinical Trials Overview 56
  • Table 51: DNA Guided Diagnostic Test - Cardiovascular Disease - Product Status 56
  • Table 52: DNA Guided Diagnostic Test - Cardiovascular Disease - Product Description 57
  • Table 53: DNA Guided Diagnostic Test - Diabetes - Product Status 57
  • Table 54: DNA Guided Diagnostic Test - Diabetes - Product Description 57
  • Table 55: DNA Guided Diagnostic Test - Obesity - Product Status 58
  • Table 56: DNA Guided Diagnostic Test - Obesity - Product Description 58
  • Table 57: INFINITI CFTR-31 Assay - Product Status 58
  • Table 58: INFINITI CFTR-31 Assay - Product Description 59
  • Table 59: INFINITI Factor II-V And MTHFR Assay - Product Status 59
  • Table 60: INFINITI Factor II-V And MTHFR Assay - Product Description 59
  • Table 61: INFINITI FMF Assay - Product Status 60
  • Table 62: INFINITI FMF Assay - Product Description 60
  • Table 63: INFINITI MTHFR Assay - Product Status 60
  • Table 64: INFINITI MTHFR Assay - Product Description 61
  • Table 65: INFINITI SMART - Factor II - Product Status 61
  • Table 66: INFINITI SMART - Factor II - Product Description 61
  • Table 67: INFINITI SMART - Factor V - Product Status 62
  • Table 68: INFINITI SMART - Factor V - Product Description 62
  • Table 69: INFINITI SMART - MTHFR - Product Status 62
  • Table 70: INFINITI SMART - MTHFR - Product Description 63
  • Table 71: INFINITI System Assay For Factor II - Product Status 63
  • Table 72: INFINITI System Assay For Factor II - Product Description 63
  • Table 73: INFINITI System Assay For Factor II-V Leiden - Product Status 64
  • Table 74: INFINITI System Assay For Factor II-V Leiden - Product Description 64
  • Table 75: INFINITI System Assay For Factor V Leiden - Product Status 64
  • Table 76: INFINITI System Assay For Factor V Leiden - Product Description 65
  • Table 77: Avellino Lab USA Inc Pipeline Products & Ongoing Clinical Trials Overview 66
  • Table 78: Keratoconus Screening Test - Product Status 66
  • Table 79: Keratoconus Screening Test - Product Description 66
  • Table 80: Baylor College of Medicine Pipeline Products & Ongoing Clinical Trials Overview 67
  • Table 81: Diagnostic Assay - Rett Syndrome - Product Status 67
  • Table 82: Diagnostic Assay - Rett Syndrome - Product Description 67
  • Table 83: BCML GmbH Pipeline Products & Ongoing Clinical Trials Overview 68
  • Table 84: Prenatal Diagnosis Biochip - Product Status 68
  • Table 85: Prenatal Diagnosis Biochip - Product Description 68
  • Table 86: BioCeps (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 69
  • Table 87: Prenatal Diagnostic Test - Product Status 69
  • Table 88: Prenatal Diagnostic Test - Product Description 69
  • Table 89: Biocept Inc Pipeline Products & Ongoing Clinical Trials Overview 70
  • Table 90: preCEED - Product Status 70
  • Table 91: preCEED - Product Description 70
  • Table 92: Celula Inc Pipeline Products & Ongoing Clinical Trials Overview 71
  • Table 93: Non-Invasive Pre-Natal Test - Product Status 71
  • Table 94: Non-Invasive Pre-Natal Test - Product Description 71
  • Table 95: Center for Biomedical Research in Network of Rare Diseases Pipeline Products & Ongoing Clinical Trials Overview 72
  • Table 96: Diagnostic Kit - HHT - Product Status 72
  • Table 97: Diagnostic Kit - HHT - Product Description 72
  • Table 98: Children's Hospital Boston Pipeline Products & Ongoing Clinical Trials Overview 73
  • Table 99: Diagnostic Assay - Cystic Fibrosis - Product Status 73
  • Table 100: Diagnostic Assay - Cystic Fibrosis - Product Description 73
  • Table 101: Diagnostic Assay - Developmental Delay - Product Status 74
  • Table 102: Diagnostic Assay - Developmental Delay - Product Description 74
  • Table 103: China Medical Technologies Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 75
  • Table 104: SPR Based DNA Chip - Coagulation Related Disorders - Product Status 75
  • Table 105: SPR Based DNA Chip - Coagulation Related Disorders - Product Description 75
  • Table 106: ChipCare Corp Pipeline Products & Ongoing Clinical Trials Overview 76
  • Table 107: HIV Assay - Infants - Product Status 76
  • Table 108: HIV Assay - Infants - Product Description 76
  • Table 109: Chronix Biomedical Inc Pipeline Products & Ongoing Clinical Trials Overview 77
  • Table 110: Companion Diagnostic Test - HPV - Product Status 77
  • Table 111: Companion Diagnostic Test - HPV - Product Description 77
  • Table 112: Cincinnati Children's Hospital Medical Center Pipeline Products & Ongoing Clinical Trials Overview 78
  • Table 113: Diagnostic Assay - Asthma - Product Status 78
  • Table 114: Diagnostic Assay - Asthma - Product Description 78
  • Table 115: Diagnostic Assay - Crohn's Disease - Product Status 79
  • Table 116: Diagnostic Assay - Crohn's Disease - Product Description 79
  • Table 117: Diagnostic Biomarker - Biliary Atresia - Product Status 79
  • Table 118: Diagnostic Biomarker - Biliary Atresia - Product Description 80
  • Table 119: Fetal Maturity Assessment Test - Product Status 80
  • Table 120: Fetal Maturity Assessment Test - Product Description 80
  • Table 121: Gene Chip Based Diagnostic Test - Liver Diseases - Product Status 81
  • Table 122: Gene Chip Based Diagnostic Test - Liver Diseases - Product Description 81
  • Table 123: Genetic Marker Diagnostic Test - Food Allergy - Product Status 81
  • Table 124: Genetic Marker Diagnostic Test - Food Allergy - Product Description 82
  • Table 125: Columbia University Pipeline Products & Ongoing Clinical Trials Overview 83
  • Table 126: Biomarker-Based Diagnostic Test - Autism - Product Status 83
  • Table 127: Biomarker-Based Diagnostic Test - Autism - Product Description 83
  • Table 128: Diagnostic Biomarker Test - Schizophrenia - Product Status 84
  • Table 129: Diagnostic Biomarker Test - Schizophrenia - Product Description 84
  • Table 130: Da An Gene Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 85
  • Table 131: Real Time PCR Kit - Alpha-Mediterranean Anaemia - Product Status 85
  • Table 132: Real Time PCR Kit - Alpha-Mediterranean Anaemia - Product Description 85
  • Table 133: Real Time PCR Kit - Beta-Mediterranean Anaemia - Product Status 86
  • Table 134: Real Time PCR Kit - Beta-Mediterranean Anaemia - Product Description 86
  • Table 135: Decipher GenX, Inc. Pipeline Products & Ongoing Clinical Trials Overview 87
  • Table 136: Diagnostic Assay - Athletic Overtraining - Product Status 87
  • Table 137: Diagnostic Assay - Athletic Overtraining - Product Description 87
  • Table 138: Diagnostic Test - Chronic Fatigue Syndrome - Product Status 88
  • Table 139: Diagnostic Test - Chronic Fatigue Syndrome - Product Description 88
  • Table 140: Diagnostic Test - Fibromyalgia - Product Status 88
  • Table 141: Diagnostic Test - Fibromyalgia - Product Description 89
  • Table 142: Diagnostic Test - Major Depression - Product Status 89
  • Table 143: Diagnostic Test - Major Depression - Product Description 89
  • Table 144: D-Kimia, LLC. Pipeline Products & Ongoing Clinical Trials Overview 90
  • Table 145: Diagnostic Assay - Malaria - Product Status 90
  • Table 146: Diagnostic Assay - Malaria - Product Description 90
  • Table 147: Diagnostic Assay - Tuberculosis - Product Status 91
  • Table 148: Diagnostic Assay - Tuberculosis - Product Description 91
  • Table 149: Duke University Pipeline Products & Ongoing Clinical Trials Overview 92
  • Table 150: Diagnostic Blood Test - Respiratory Infections - Product Status 92
  • Table 151: Diagnostic Blood Test - Respiratory Infections - Product Description 92
  • Table 152: DxTerity Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 93
  • Table 153: RadTox Test - Product Status 93
  • Table 154: RadTox Test - Product Description 93
  • Table 155: ELITechGroup Inc Pipeline Products & Ongoing Clinical Trials Overview 94
  • Table 156: Eon 100 Automated Chemistry Analyzer - UIBC Assay - Product Status 94
  • Table 157: Eon 100 Automated Chemistry Analyzer - UIBC Assay - Product Description 94
  • Table 158: Epinex Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 95
  • Table 159: Down Syndrome Screen Test - Product Status 95
  • Table 160: Down Syndrome Screen Test - Product Description 95
  • Table 161: Eppendorf AG Pipeline Products & Ongoing Clinical Trials Overview 96
  • Table 162: Rheumagene Diagnostic Test - Product Status 96
  • Table 163: Rheumagene Diagnostic Test - Product Description 96

List of Figures

1.2 List of Figures

  • Figure 1: Inborn Gene or Chromosome Alterations Diagnostic Tests - Pipeline Products by Stage of Development 25
  • Figure 2: Inborn Gene or Chromosome Alterations Diagnostic Tests - Pipeline Products by Territory 26
  • Figure 3: Inborn Gene or Chromosome Alterations Diagnostic Tests - Pipeline Products by Regulatory Path 27
  • Figure 4: Inborn Gene or Chromosome Alterations Diagnostic Tests - Pipeline Products by Estimated Approval Date 28
  • Figure 5: Inborn Gene or Chromosome Alterations Diagnostic Tests - Ongoing Clinical Trials 29
Back to Top